Gepotidacin for gonorrhea

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 8 Jul 2019: Trial registered, NCT04010539
  2. 21 Oct 2019: Trial started, NCT04010539

The trials

NCT02294682: A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae

State
Completed
Phase
Phase 2
People
106 taking part
Started
15 Apr 2015
Primary completion
1 Jul 2016
Arms
GSK2140944 1500 mg, GSK2140944 3000 mg
Results
Posted on the registry
  1. 19 Nov 2014: Trial registered
  2. 27 Jul 2016: Trial completed
  3. 23 May 2017: Trial results posted

NCT04010539: A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

State
Completed
Phase
Phase 3
People
628 taking part
Started
21 Oct 2019
Primary completion
10 Oct 2023
Arms
Participants receiving Gepotidacin
Results
Posted on the registry
  1. 8 Jul 2019: Trial registered
  2. 21 Oct 2019: Trial started
  3. 10 Oct 2023: Trial completed
  4. 30 May 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.